Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Parkinson’s Protein has Widespread and Conserved Toxicity Influence

The authors built molecular networks in yeast cells and in neurons to draw relationships between different genetic forms of Parkinson’s (stylized as patients in different colors) and the aggregation of the protein a-synuclein (at center in red). [Vikram Khuran

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The authors built molecular networks in yeast cells and in neurons to draw relationships between different genetic forms of Parkinson’s (stylized as patients in different colors) and the aggregation of the protein a-synuclein (at center in red). [Vikram Khurana, Chee Yeun Chung]

Through two publications and a large collaboration, led by researchers at Whitehead Institute and Massachusetts Institute of Technology (MIT), investigators have just described their use of a suite of novel biological and computational methods to shed light on how the misfolding of α-synuclein protein in neurons relates to the growing number of genes implicated in Parkinson’s disease (PD). The findings from these studies were published recently in Cell Systems in articles entitled “Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways” and “In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons.”

The scientists initiated their analysis by creating two ways to systematically map the footprint of α-synuclein within living cells. “In the first paper, we used powerful and unbiased genetic tools in the simple Baker's yeast cell to identify 332 genes that impact the toxicity of α-synuclein,” explained lead author for one of the papers Vikram Khurana, M.D., Ph.D., principal investigator within the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and the Harvard Stem Cell Institute, and first and co-corresponding author on the studies. “Among them were multiple genes known to predispose individuals to Parkinson's—so we show that various genetic forms of Parkinson's are directly related to α-synuclein. Moreover, the results showed that many effects of alpha-synuclein have been conserved across a billion years of evolution from yeast to human.”

The investigators also looked at mapping all of the interactions of α-synuclein and its locale within neurons at various time points. This was achieved without disturbing the native environment of the neuron, by tagging α-synuclein with an enzyme—APEX—that allowed proteins less than 10 nanometers away from α-synuclein to be marked with a trackable fingerprint.

“In the second paper, we created a spatial map of α-synuclein, cataloging all the proteins in living neurons that were in close proximity to the protein,” remarked lead author Chee Yeun Chung, Ph.D. former Whitehead Institute senior research scientist and now scientific co-founder and associate director at Yumanity Therapeutics. “As a result, for the first time, we were able to visualize the protein's location, at minute scale, under physiologic conditions in an intact brain cell.”

Interestingly, the maps the researchers derived from these two processes were closely related and converged on the same Parkinson's genes and cellular processes. Whether in a yeast cell or a neuron, α-synuclein directly interfered with the rate of production of proteins in the cell and the transport of proteins between cellular compartments.

“It turns out the mechanisms of toxicity of the misfolded protein are closely related to which proteins it directly interacts with, and that these interactions can explain connections between different Parkinson's genetic risk factors,” Dr. Khurana noted.

In assembling the massive amount of data they collected, the investigators needed to address two major challenges that scientists often face when generating large datasets of individual genes and proteins in model organisms like yeast: How to assemble the data into coherent maps? And how to integrate information across species, in this case from yeast to human?

“First, we had to figure out much better methods to find human counterparts of yeast genes, and then we had to arrange the humanized set of genes in a meaningful way,” explained co-author Jian Peng, Ph.D., assistant professor of computer sciences at University of Illinois, Urbana-Champaign. “The result was TransposeNet, a new suite of computational tools that uses machine learning algorithms to visualize patterns and interaction networks based on genes that are highly conserved from yeast to humans—and then makes predictions about the additional genes that are part of the α-synuclein toxicity response in humans.”

This new analysis produced networks that mapped out how α-synuclein is related to other Parkinson's genes through well-defined molecular pathways. “We now have a system to look at how seemingly unrelated genes come together to cause Parkinson's and how they are related to the protein that misfolds in this disease,” Dr. Khurana stated.

To confirm their work, the researchers generated neurons from Parkinson's patients with different genetic forms of the disease. They showed that the molecular maps generated from their analyses allowed them to identify abnormalities shared among these distinct forms of Parkinson's. Prior to this, there was no obvious molecular connection between the genes implicated in these varieties of PD. “We believe these methods could pave the way for developing patient-specific treatments in the future,” Dr. Khurana concluded.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →